Lorcaserin ( DrugBank: Lorcaserin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 140 | Dorabe syndrome | 2 |
140. Dorabe syndrome
Clinical trials : 116 / Drugs : 65 - (DrugBank : 17) / Drug target genes : 50 - Drug target pathways : 64
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04572243 (ClinicalTrials.gov) | September 23, 2020 | 30/9/2020 | A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome | Epilepsies, Myoclonic | Drug: Placebo;Drug: Lorcaserin | Eisai Inc. | NULL | Recruiting | 2 Years | N/A | All | 58 | Phase 3 | United States;Canada |
| 2 | NCT04457687 (ClinicalTrials.gov) | June 7, 2018 | 30/6/2020 | Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies | Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies | Epilepsies, Myoclonic;Drug Resistant Epilepsy | Drug: Lorcaserin | Eisai Inc. | NULL | Available | 2 Years | N/A | All | NULL |